Compare VALE & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALE | RMD |
|---|---|---|
| Founded | 1942 | 1989 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | VALE | RMD |
|---|---|---|
| Price | $12.69 | $250.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $12.90 | ★ $292.27 |
| AVG Volume (30 Days) | ★ 34.5M | 864.7K |
| Earning Date | 10-30-2025 | 01-29-2026 |
| Dividend Yield | ★ 5.75% | 0.95% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | 1.32 | ★ 9.77 |
| Revenue | ★ $40,027,019,862.00 | $5,257,400,000.00 |
| Revenue This Year | N/A | $9.85 |
| Revenue Next Year | $5.23 | $7.32 |
| P/E Ratio | ★ $9.59 | $25.82 |
| Revenue Growth | 1.05 | ★ 9.36 |
| 52 Week Low | $8.06 | $199.92 |
| 52 Week High | $13.62 | $293.81 |
| Indicator | VALE | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 48.59 |
| Support Level | $12.61 | $245.97 |
| Resistance Level | $13.40 | $259.99 |
| Average True Range (ATR) | 0.28 | 5.40 |
| MACD | -0.02 | 0.59 |
| Stochastic Oscillator | 40.38 | 62.13 |
Vale is a large global miner and the world's largest producer of iron ore and pellets. In recent years the company has sold noncore assets such as its fertilizer, coal, and steel operations to concentrate on iron ore, nickel, and copper. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets. The base metals division is much smaller, consisting of nickel mines and smelters along with copper mines producing copper in concentrate. In 2024, Vale sold a minority 10% stake in energy transition metals, its base metals business, likely the first step in separating base metals and iron ore.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.